Martina Garau
Martina has 20 years of experience leading projects for a variety of organisations, including global life sciences companies, non-profit research organisations, charities and trade associations. Her projects aim at expanding the evidence used in healthcare resource allocation decisions and shaping the debate around critical health policy issues. Her areas of expertise include value assessments in high- and middle- income countries; HTA reforms and collaborations; measuring and incorporating societal impacts of interventions in decision-making; economic issues posed by the development and provision of orphan medicines; paying for innovative therapies, including combination; and structured approaches to mulit-criteria healthcare decision–making.
Publications and Insights
- Insight: How Widely Are QALYs Used in OECD Countries? A Snapshot of International Practices
- Insight: Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA
- Publication: The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
- Insight: Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
- Publication: Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
- Publication: A Framework for Value-aligned Pricing of Combination Therapies
- Publication: How Have HTA Agencies Evolved Their Methods Over Time?
- Publication: The Socioeconomic Burden Of Cervical Cancer in the UK: What are the benefits of achieving the WHO elimination target?
- Publication: NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
- Publication: Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment
- Bulletin: Advancing HTA through collaboration
- Insight: Around The World in HTAs: Italy – What’s Next?
- Insight: Combination Therapies: A Step Forward to the Value Attribution Problem
- Publication: Navigating the Landscape of Digital Health – United Kingdom
- Insight: New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
- Publication: When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
- Publication: The Lower Drug Costs Now Act and Pharmaceutical Innovation
- Publication: How is Quality of Life Measured for Health Technology Assessments?
- Publication: Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
- Publication: International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
- Publication: Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?
- Publication: Unrelieved Pain in Palliative Care in England
- Publication: How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
- Publication: Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
- Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
- Publication: Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
- Publication: Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
- Publication: Policy Options for Formulary Development in Middle-income Countries
- Publication: Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
- Publication: Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
- Publication: Obstructive Sleep Apnoea: Health Economics Report
- Publication: Exploring the Interdependencies of Research Funders in the UK
- Publication: Exploring the link between health and wealth in decision making
- Publication: Multi-Criteria Decision Analysis to Value Orphan Medicines
- Publication: Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
- Publication: Exploring the Interdependency between Public and Charitable Medical Research
- Publication: Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
- Publication: Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society
- Publication: Using QALYs in Cancer: Review of the Methodological Limitations
- Publication: Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries
- Publication: Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience
- Publication: European Medicines Pricing and Reimbursement: Now and the Future
- Publication: Estimating Pharmaceutical Companies’ Value to the Nation: Case Study of the British Pharma Group